Previous studies showed that treatment with beta-blockers improves LV remodeling and clinical outcomes in patients with symptomatic heart failure due to systolic LV dysfunction, but to date there has ...

Beta-blockers have been the initial treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM) despite limited evidence of their efficacy. Aficamten is a cardiac myosin inhibitor that ...

OBJECTIVE: Sibutramine is an effective appetite suppresser agent, but treatment is often complicated with side effects, including palpitations and hypertension. In this study, we aimed to assess the ...

Metoprolol (Metapro ) is a beta-blocker, prescribed for high blood pressure either alone or with other medications. It is also used for chest pain, migraine and hyperthyroidism. It reduces elevated ...

For the above reasons, Medindia cannot be held liable for any action taken based on the information provided by its website. The purpose of this website is to provide initial guidance only and it does ...

Dr. Keith Roach writes a medical question-and-answer column weekdays. Dear Dr. Roach: My husband has been on metoprolol for about eight years. He was prescribed that medication right after he had a ...

Metoprolol tartrate is taken up to four times a day because it works quickly. Metoprolol succinate is taken once a day and works over 24 hours. Both forms treat high blood pressure and angina, but ...

Previous studies have shown a benefit of beta-blockers in the reduction of exacerbations and death in patients with COPD, despite the presence of cardiac disease. A recent study hypothesized that the ...

Metoprolol is a medicine used to treat high blood pressure and heart problems, but it can interact with other drugs and substances. These include certain heart and blood pressure medicines like ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

The Department of Pharmaceuticals (DoP) has rejected review applications from five companies including AstraZeneca and Lupin while upholding the ceiling price fixed for various strengths of modified ...